Danaher Corporation (NYSE:DHR) shares traded 0.82% higher at $257.98 on Wall Street last session.
In accordance with the data, 28 analysts cover Danaher Corporation (NYSE:DHR). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $328.00 and a low of $220.00, we find $270.50. Given the previous closing price of $255.88, this indicates a potential upside of 5.71 percent. DHR stock price is now 9.63% away from the 50-day moving average and 2.63% away from the 200-day moving average. The market capitalization of the company currently stands at $181.81B.
It has been rated a hold by 7 analysts and a buy by 17. Brokers who have rated the stock have averaged $274.36 as their price target over the next twelve months.
With the price target of $270, Raymond James recently initiated with Outperform rating for Danaher Corporation (NYSE: DHR).
In other news, Raskas Daniel, SVP – Corporate Development sold 19,847 shares of the company’s stock on May 31. The stock was sold for $4,535,040 at an average price of $228.50. Upon completion of the transaction, the SVP – Corporate Development now directly owns 38,673 shares in the company, valued at $9.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 05, Director LOHR WALTER G sold 3,490 shares of the business’s stock. A total of $840,685 was realized by selling the stock at an average price of $240.88. This leaves the insider owning 12,115 shares of the company worth $3.13 million. Insiders disposed of 1,433,951 shares of company stock worth roughly $369.93 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DHR stock. A new stake in Danaher Corporation shares was purchased by GENERATION INVESTMENT MANAGEMENT LLP during the first quarter worth $383,060,000. D1 CAPITAL PARTNERS L.P. invested $233,730,000 in shares of DHR during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Danaher Corporation valued at approximately $177,794,000. OFI INVEST ASSET MANAGEMENT acquired a new stake in DHR for approximately $103,254,000. WOODLINE PARTNERS LP purchased a new stake in DHR valued at around $45,445,000 in the second quarter. In total, there are 2,872 active investors with 81.00% ownership of the company’s stock.
During the past 12 months, Danaher Corporation has had a low of $221.22 and a high of $303.82. As of last week, the company has a debt-to-equity ratio of 0.40, a current ratio of 1.90, and a quick ratio of 1.50. According to the stock market information, the enterprise value for the company is $204.48B, which is based on a 27.76 price-to-earnings ratio, a 15.88 price-to-earnings-growth ratio, and a beta of 0.80. The fifty day moving average price for DHR is $235.80 and a two-hundred day moving average price translates $251.26 for the stock.
The latest earnings results from Danaher Corporation (NYSE: DHR) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at $2.36, beating analysts’ expectations of $2.25 by 0.11. This compares to $2.34 EPS in the same period last year. The net profit margin was 22.10% and return on equity was 14.50% for DHR. The company reported revenue of $7.17 billion for the quarter, compared to $7.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.78 percent. For the current quarter, analysts expect DHR to generate $7.11B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 07/28/2023. Investors who held shares on 06/30/2023 were paid a $0.27 dividend. On an annualized basis, this represents a $1.08 dividend and a 0.42% percent yield. There was an ex-dividend date of 06/29/2023 for this dividend. In terms of dividend payout ratio, DHR is presently at 10.60%.
Danaher Corporation(DHR) Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
